These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 14733726)

  • 21. Drotrecogin alfa: a second look. More clinical trials in severe sepsis: mostly negative results.
    Prescrire Int; 2007 Feb; 16(87):7-9. PubMed ID: 17323514
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human CD14 is an efficient target for recombinant immunoglobulin vaccine constructs that deliver T cell epitopes.
    Tunheim G; Schjetne KW; Fredriksen AB; Sandlie I; Bogen B
    J Leukoc Biol; 2005 Mar; 77(3):303-10. PubMed ID: 15576418
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phosphatidyl inositol-3-phosphate kinase mediates CD14 dependent signaling.
    O'Toole T; Peppelenbosch MP
    Mol Immunol; 2007 Mar; 44(9):2362-9. PubMed ID: 17126402
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-human CD14 monoclonal antibody improves survival following sepsis induced by endotoxin, but not following polymicrobial infection.
    Nakamura M; Takeuchi T; Shirakawa K; Furusako S
    Eur J Pharmacol; 2017 Jul; 806():18-24. PubMed ID: 28322834
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase 1b dose-escalation, safety, and pharmacokinetic study of IC14, a monoclonal antibody against CD14, for the treatment of amyotrophic lateral sclerosis.
    Henderson RD; Agosti JM; McCombe PA; Thorpe K; Heggie S; Heshmat S; Appleby MW; Ziegelaar BW; Crowe DT; Redlich GL
    Medicine (Baltimore); 2021 Oct; 100(42):e27421. PubMed ID: 34678870
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Pharmacotherapy of sepsis].
    Guzzo I; Morabito S; Stucchi R; Poli G; Fumagalli R
    G Ital Nefrol; 2006; 23 Suppl 36():S79-86. PubMed ID: 17068734
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and activity of anti-CD14 antibody IC14 (atibuclimab) in ALS: Experience with expanded access protocol.
    Gelevski D; Addy G; Rohrer M; Cohen C; Roderick A; Winter A; Carey J; Scalia J; Yerton M; Weber H; Doyle M; Parikh N; Kane G; Ellrodt A; Burke K; D'Agostino D; Sinani E; Yu H; Sherman A; Agosti J; Redlich G; Charmley P; Crowe D; Appleby M; Ziegelaar B; Hanus K; Li Z; Babu S; Nicholson K; Luppino S; Berry J; Baecher-Allan C; Paganoni S; Cudkowicz M
    Muscle Nerve; 2023 May; 67(5):354-362. PubMed ID: 36533976
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Monoclonal antibodies against inflammatory mediators for the treatment of patients with sepsis].
    Matsubara T
    Nihon Rinsho; 2002 Mar; 60(3):578-84. PubMed ID: 11904976
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modulation of human leukocyte antigen-DR on monocytes and CD16 on granulocytes in patients with septic shock using hemoperfusion with polymyxin B-immobilized fiber.
    Ono S; Tsujimoto H; Matsumoto A; Ikuta S; Kinoshita M; Mochizuki H
    Am J Surg; 2004 Aug; 188(2):150-6. PubMed ID: 15249240
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hemoperfusion with polymyxin B-immobilized fibers reduced the number of CD16+ CD14+ monocytes in patients with septic shock.
    Tsujimoto H; Ono S; Hiraki S; Majima T; Kawarabayashi N; Sugasawa H; Kinoshita M; Hiraide H; Mochizuki H
    J Endotoxin Res; 2004; 10(4):229-37. PubMed ID: 15373966
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Common TNF-alpha, IL-1 beta, PAI-1, uPA, CD14 and TLR4 polymorphisms are not associated with disease severity or outcome from Gram negative sepsis.
    Jessen KM; Lindboe SB; Petersen AL; Eugen-Olsen J; Benfield T
    BMC Infect Dis; 2007 Sep; 7():108. PubMed ID: 17877801
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low HLA-DR expression on CD14+ monocytes of burn victims with sepsis, and the effect of carbachol in vitro.
    Yang HM; Yu Y; Chai JK; Hu S; Sheng ZY; Yao YM
    Burns; 2008 Dec; 34(8):1158-62. PubMed ID: 18538934
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The clinical relevance of endotoxin in human sepsis: a critical analysis.
    Opal SM
    J Endotoxin Res; 2002; 8(6):473-6. PubMed ID: 12697093
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Monoclonal antibodies against endotoxin in septicemia. Marketing or scientific evaluation?].
    Waage A
    Tidsskr Nor Laegeforen; 1994 Mar; 114(8):951-3. PubMed ID: 8191476
    [No Abstract]   [Full Text] [Related]  

  • 35. Clinical studies of monoclonal anti-lipid A antibody XMMEN-0E5.
    Harkonen S; Kennedy D; Greenberg R
    Prog Clin Biol Res; 1988; 272():395-406. PubMed ID: 3293083
    [No Abstract]   [Full Text] [Related]  

  • 36. Antipyretic therapy in patients with sepsis.
    Hasday JD; Garrison A
    Clin Infect Dis; 2000 Oct; 31 Suppl 5():S234-41. PubMed ID: 11113029
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Applications of molecular biology and biotechnology: antibody therapy of sepsis.
    Wheeler AP; Bernard GR
    J Crit Care; 1996 Jun; 11(2):77-94. PubMed ID: 8727029
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Do we owe something?].
    Fomsgaard A
    Ugeskr Laeger; 2000 Jul; 162(27):3876-7. PubMed ID: 10920709
    [No Abstract]   [Full Text] [Related]  

  • 39. [Mechanisms in sepsis induced by gram positive microorganisms].
    Kronborg G
    Ugeskr Laeger; 2000 May; 162(20):2852-4. PubMed ID: 10860419
    [No Abstract]   [Full Text] [Related]  

  • 40. Human monoclonal antibody effective against septicemia.
    Oncology (Williston Park); 1990 Nov; 4(11):74. PubMed ID: 2150328
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.